2010/04/20 - A new publication from GenoSplice is available in PubMed - We applied our EASANA® platform to analyze the effect of estrogen treatments on the gene expression regulation at the exon level on a breast cancer cell line (collaboration with INSERM and the Curie Institute)... GenoSplice technology's news -GenoSplice - Corporate Profile
GenoSplice technology is a privately held biotech company leader in transcriptomic data analysis.
The company provides bioinformatics services for international academic laboratories, biotechs and pharmas (e.g., Curie Institute, Pasteur Institute, University of Cambridge, University of Kentucky, Howard Hugues Medical Institute…) and is the Official Service Provider of EURASNET, the European Network of Excellence on Alternative Splicing (gathering 41 research teams from 11 European countries, as well as the USA, Israel and Argentina).
GenoSplice is involved in several international partnerships with industries and academics institutes.
GenoSplice technical developments are focused on development of innovative useful and powerful solutions to take full advantage of new technologies such as high-throughput sequencing. Finally, the company develops R&D projects in collaboration with clinicians in order to identify molecular biomarkers from alternative splicing in cancer... GenoSplice technology : Corporate Profile -
